Testing a new drug for B-cell blood cancers that have returned
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new experimental medicine (SYS6055 injection) for people with B-cell blood cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The goal is to see if it is safe and how well it works against cancer cells that have the CD19 marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of blood cancer (B-cell leukemia or lymphoma) that is CD19-positive, meaning it has a specific marker on the cells
- Your cancer has come back or not responded to standard treatments
- You have at least one tumor that can be measured (by scans)
- You are able to care for yourself (ECOG score 0 or 1) and expected to live at least 3 more months
- You have adequate organ and bone marrow function (checked by blood tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug, SYS6055, for people with an aggressive type of B-cell lymphoma that has come back or not responded to standard treatment. The goal is to see if the drug can help shrink tumors and control the disease.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new medicine called WGb-0301, given by injection, for people with certain blood cancers (B-cell lymphoma or lymphocytic leukemia) that have come back or not improved with other treatments. The goal is to see if this drug can help control the cancer and what side effects it might cause.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Hear when a new Relapsed/Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.